Ovarian Cancer – Current Treatment – Current Treatment: Physician Insights – Ovarian Cancer (US)
Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing decisions. The use of Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Pharma&) as maintenance therapy across multiple lines and biomarker-defined patient populations is creating new sequencing dynamics. Elahere, set to be the standard of care for FRα-positive patients, is having an impact on the treatment algorithm for platinum-resistant disease.
Questions answered
- What is the patient share of key therapies for advanced-stage ovarian cancer by line of therapy?
- What factors influence physicians’ choice of first-line maintenance treatment (e.g., Lynparza plus bevacizumab versus Zejula) for advanced-stage ovarian cancer?
- What are the key drivers of and barriers to the use of select drugs for advanced-stage ovarian cancer?
- How do drug-treatment rates vary between key ovarian cancer patient populations, according to stage of disease and line of therapy?
Markets covered: United States
Primary research: Survey of 100 U.S. medical oncologists fielded in April 2024
Key drugs: bevacizumab, Lynparza, Zejula, Rubraca, and Elahere
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
